Cerecor announces positive results for CERC-002 in Crohn’s disease treatment
Click Here to Manage Email Alerts
Cerecor reported positive initial results from a trial analyzing CERC-002 for the treatment of patients with moderate to severe Crohn’s disease, according to a press release.
In a phase 1b, open-label, dose-escalation study, researchers analyzed the safety, tolerability and short-term efficacy of CERC-002, an investigational fully human anti-LIGHT (homologous to Lymphotoxin, exhibits inducible expression and competes with HSV glycoprotein D for binding to herpesvirus entry mediator, a receptor expressed on T lymphocytes) monoclonal antibody, among patients with CD who previously experienced failure with anti-tumor necrosis factor-alpha treatment. Patients received CERC-002 1 mg/kg and CERC-002 3 mg/kg subcutaneously at 14-day intervals with dose escalation occurring every 2 weeks. Following 8-weeks of treatment, researchers noted rapid response with a mean reduction in LIGHT levels of approximately 80% compared with baseline, colonoscopy confirmed endoscopic improvement in 75% of patients.
“We are delighted with the therapeutic response and favorable safety and tolerability profile observed in this initial cohort of our phase 1b study for CERC-002 in moderate to severe Crohn’s disease [patients] refractory to biologics and we plan to proceed into further clinical development,” H. Jeffrey Wilkins, MD, chief medical officer of Cerecor said in the release. “Later this year, we expect to report additional efficacy and safety data from the high dose cohort for this ongoing open-label study and intend to use those data as an important component of the design of the next clinical study. These encouraging results are our second positive proof-of-concept with this novel first-in-class monoclonal antibody and we believe further validate the LIGHT mechanism of action in both acute and chronic inflammatory diseases.”
Read more about
Click Here to Manage Email Alerts